Article
Efficacy of WWQ-131, a highly selective JAK2 inhibitor, in mouse models of myeloproliferative neoplasms.
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie - 1 Dec 2022
Ge Huan, Wang Caolin, Tian Chaoquan, Diao Yanyan, Wang Wanqi, Ma Xiangyu, Zhang Jian, Li Honglin, Zhao Zhenjiang, Zhu Lili
Abstract excerpt
Hyperactivation of the Janus kinase 2 (JAK2) signaling pathway leads to myeloproliferative neoplasms (MPNs) and targeting JAK2 can be used as an effective strategy for the treatment of MPNs. Here, our study indicated that WWQ-131 was a highly selective JAK2 inhibitor (IC50 =2.36 nM), with 182-fold and 171-fold more selective to JAK1 and JAK3, respectively. In JAK2V617F-dependent cell lines, WWQ-131 efficaciously...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.